Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 71-80 of 525 results
Spine Surg Relat Res, 2022 • December 27, 2021
This multicenter study investigated whether antiplatelet/anticoagulant (APAC) drugs affect blood loss during surgery for cervical spine trauma in elderly patients. The study found no significant incre...
KEY FINDING: APAC use in elderly patients was not significantly associated with surgical blood loss according to the IPTW method with propensity scoring or linear mixed model analyses.
Frontiers in Neuroscience, 2022 • August 11, 2022
This systematic review examined the efficacy of metformin in treating spinal cord injuries (SCI) in rats. The review included 12 studies and analyzed the effects of metformin on neurological function ...
KEY FINDING: Metformin treatment was associated with increased Basso, Beattie, and Bresnahan (BBB) scores, indicating improved locomotor function in rats with SCI.
Neuropsychopharmacology, 2022 • September 30, 2022
This article is a correction to a previously published study concerning the association of GFAP concentration and posttraumatic stress disorder in patients with mild traumatic brain injury. The correc...
KEY FINDING: The primary finding is a correction of the material measured; GFAP was measured in plasma, not serum, in the original study.
The Journal of Spinal Cord Medicine, 2020 • July 1, 2020
This study investigated the safety of fenofibrate therapy in persons with SCI to determine the safety profile of 4 months of once-daily fenofibrate treatment when initiated using modified intervention...
KEY FINDING: Four out of 15 participants experienced an adverse event, including gastrointestinal distress and elevated liver enzymes, leading to three subjects discontinuing the medication.
Physiological Reports, 2019 • October 1, 2019
This study compared the effects of abaloparatide and teriparatide on bone structure, turnover, and signaling pathways in mice and cells. The results showed that abaloparatide had a greater osteoanabol...
KEY FINDING: Abaloparatide caused a greater dose-dependent increase in cortical thickness than teriparatide.
Spinal Cord Series and Cases, 2019 • September 1, 2019
This randomized, double-blinded, placebo-controlled, crossover study explored the effectiveness of botulinum toxin A (BoNTA) for treating at-level spinal cord injury (SCI) pain. Although the data did ...
KEY FINDING: A higher proportion of participants reported a marked change in average pain intensity from baseline to 8 and 12 weeks post-BoNTA vs. post-placebo (33% vs. 0%).
INTERNATIONAL JOURNAL OF MOlecular medicine, 2020 • January 31, 2020
The study aimed to evaluate the effect of the CX3CR1 inhibitor AZD8797 in early recovery after acute SCI and elucidate its potential mechanism in blocking inflammation and apoptosis. AZD8797 improved ...
KEY FINDING: CX3CR1 and CX3CL1 expression levels increase after spinal cord injury, peaking at 10 days, suggesting their involvement in the inflammatory response.
Spinal Cord Series and Cases, 2020 • March 27, 2020
This case report presents a 19-year-old male who developed a spinal cord injury after using ecstasy. The patient presented with rapidly progressive loss of motor function and dysesthesia in both lower...
KEY FINDING: A 19-year-old male developed a T11 AIS B SCI/D (spinal cord injury/dysfunction) following recreational use of ecstasy.
J Cell Mol Med, 2020 • August 1, 2020
This study assesses the neuroprotective effects of sitagliptin and explores the possible underlying molecular mechanism of the neuroprotection of sitagliptin after SCI both in vivo and in vitro. It wa...
KEY FINDING: Sitagliptin administration significantly increased GLP-1R protein level, alleviated neuronal apoptosis following SCI. Administration of sitagliptin significantly increased GLP-1R protein level, alleviated neuronal apoptosis
Spinal Cord Series and Cases, 2020 • July 21, 2020
This pilot study investigated the effectiveness of combining botulinum toxin A (BoNT-A) injections with electrical stimulation (ES) to improve hand function in individuals with incomplete C5–C6 and C6...
KEY FINDING: Treatments produced a significant reduction in motor spasticity (MAS) and better dexterity (NHPT) in the C6–C7 BML with respect to the WML cases